Research Journal of Pharmacy and Technology

Diabetes mellitus type-2 (DMT2), as one of chronic metabolic disease, still become a major concern in the world especially for low-middle income countries include Indonesia. The role of genetic has been known associated with the pathophysiology or treatment of DMT2, such as TCF7L2.

The objective of current study is to find the association between TCF7L2gene in DMT2 Indonesian patients.

This study enrolled 186 DMT2 patients and 30 health subjects. The treatment outcome was measured based on fasting blood glucose and hemoglobin A1C (HbA1C). Polymorphism of TCF7L2(rs7903146 (C > G/T)) was genotyped bypolymerase chain reaction (PCR).

The mean average of patients in this study is 60.47 years, and most of the patients using combination treatment (52.15%), however most of the DMT2 patients is in uncontrolled conditions. There are two genotypes TCF7L2 rs7903146 presented in this study, which are CC (wildtype) and CT (heterozygous mutant), however we could not find the TT (homozygous mutant). There are no significant association between blood glucose level-genotype variation and HbA1C-genotype variation (p value > 0.05). However, the proportion of heterozygous mutant-type in the uncontrolled group is higher than wild-type.

The variations of TCF7L2 rs7903146 is not associated with DMT2 susceptibility in Indonesian populations. However, we present the higher proportion of the wildtypeTCF7L2 rs7903146 in DMT2 subjects. There is no association between treatment outcome and genotype variation in DMT2 subjects.